乙型肝炎肝硬化食管静脉曲张风险预测列线图模型的构建与验证

    Development and validation of the nomogram model for predicting the risk of esophageal varices in hepatitis B cirrhosis

    • 摘要:
      目的 探讨乙型肝炎肝硬化病人发生食管静脉曲张的危险因素,并建立列线图模型预测食管静脉曲张发生的风险。
      方法 对收治的肝炎肝硬化病人进行回顾性队列分析。共招募了241例乙型肝炎肝硬化病人,按7∶ 3随机拆分为训练队列(169例)和验证队列(72例)。采用单因素分析和多因素logistic回归分析确定食管静脉曲张发生的危险因素。构建列线图预测HBC病人EVs发生的概率。利用ROC曲线评估列线图预测食管静脉曲张存在的准确性。采用决策曲线分析来确定列线图的临床效益。
      结果 结果显示血小板分布宽度降低、门静脉峰值流速减慢及脾脏长度增加是HBC病人发生EVs的独立危险因素(P < 0.05~P < 0.01)。成功构建列线图模型,无论是训练队列还是验证队列,列线图的校准曲线均接近于标准曲线,列线图校准良好,预测EVs发生风险的结果准确可信。DCA结果显示,在训练队列和验证队列病人中,列线图DCA曲线均位于零净效益线的上方,说明列线图可取得临床效益。
      结论 构建并验证了基于血小板分布宽度、门静脉峰值流速和脾脏长度的列线图模型,能够无创地预测乙型肝炎肝硬化病人发生食管静脉曲张的风险。

       

      Abstract:
      Objective To explore the risk factors of esophageal varices in patients with hepatitis B cirrhosis, and establish a nomogram model to predict the risk of esophageal varices(EVs).
      Methods The clinical data of patients with hepatitis B cirrhosis were with a retrospective cohort study analyzed.A total of 241 patients with hepatitis B cirrhosis were recruited, and randomly divided into the training cohort(169 cases) and validation cohort(72 cases) in a 7∶3 ratio.Univariate analysis and multivariate logistic regression analysis were used to analyze the risk factors of EVs.The nomogram to predict the probability of EVs occurrence in hepatitis B cirrhosis patients was constructed.The ROC curve was used to evaluate the accuracy of the nomogram in predicting the presence of hepatitis B cirrhosis.Decision curve analysis was adopted to determine the clinical benefits of nomogram.
      Results The results showed that the platelet distribution width decreased, and the peak velocity of portal vein slowing and spleen length increasing were the independent risk factors of EVs in hepatitis B cirrhosis patients(P < 0.05 to P < 0.01).The nomogram model was successfully constructed.Whether it was the training cohort or the validation cohort, the calibration curve of nomogram was close to the standard curve.The nomogram was well calibrated, and the results for predicting the risk of EVs occurrence were accurate and reliable.The results of DCA showed that in both the training cohort and validation cohort patients, the nomogram DCA curves were above the zero net benefit line, which indicated that the nomogram could achieve clinical benefits.
      Conclusions A nomogram model based on platelet distribution width, peak velocity portal vein of spleen length is constructed and verified, which can non-invasively predict the risk of EVs in patients with hepatitis B cirrhosis.

       

    /

    返回文章
    返回